Novartis and Medicines for Malaria Venture have launched a new pediatric formulation of the malaria treatment Coartem. The product, Coartem Dispersible, is the first artemisinin-based combination therapy (ACT) developed specifically for children, according to a company statement. Novartis will offer the product without profit for public sector use in malaria-endemic regions of Africa.